2008 American College of Chest Physicians (ACCP) Guidelines Will Increase
Use of Trellis(R) Peripheral Infusion System
NORTHBROOK, Ill., July 29 /PRNewswire/ -- The American College of Chest Physicians (ACCP) has published new evidence-based clinical guidelines for physicians that for the first time suggest the use of pharmacomechanical thrombolysis for acute iliofemoral deep vein thrombosis (DVT) in conjunction with anticoagulation drug therapy. The new guidelines appear in the July supplement to the CHEST journal.
"This is a major change in the recommendations for the care of these patients with extensive DVT, and represents a major advance in treatment. Adopting an initial strategy of thrombus removal will improve the quality of life of these patients and potentially avoid recurrent DVT in the future," stated Anthony J. Comerota, MD, FACS, FACC, Director of the Jobst Vascular Center and Adjunct Professor of Surgery, University of Michigan.
"The recommendation to treat certain cases of acute DVT with pharmacomechanical thrombolysis adds an important tool to help treat the acute problem as well as to minimize the long-term disability of post-thrombotic syndrome (PTS) in patients," added Katharine L. Krol, MD, Director, Vascular Interventional Radiology, CorVasc MDs, Indianapolis, IN and recent past president of the Society of Interventional Radiology (SIR).
The new Venous Thromboembolic (VTE) Disease guidelines represent an evolution from the previous ACCP standard which recommended the use of anticoagulation drug therapy alone for the treatment of DVT. For complete information on the new ACCP VTE Guidelines, visit http://www.TheNewGuidelines.org.
While anticoagulation alone mitigates the risk of clot propagation and
pulmonary embolism, it often fails to clear the blockage. This residual
thrombus can lead to venous hypertension, valvular insufficienc
|SOURCE Bacchus Vascular, Inc.|
Copyright©2008 PR Newswire.
All rights reserved